Log In
person
Innoviva Inc
INVA
summarize
3 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Royalties from Licensing of Pharma to Pharma Production Companies |
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
238.85M | 76.93% |
| Royalties from Licensing of Pharma to Pharma Production Companies |
Branded Pharmaceuticals (outsourced)
These companies research, develop, and outsource the manufacturing of patented drugs.
|
60.62M | 19.52% |
| Royalties from Licensing of Pharma to Pharma Production Companies |
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
11M | 3.54% |
| keyboard_arrow_down |
Royalties from Licensing of Pharma to Pharma Production Companies
Pharmaceutical Patent Licensing
|
238.85M | 76.93% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||
| keyboard_arrow_down |
Royalties from Licensing of Pharma to Pharma Production Companies
Branded Pharmaceuticals (outsourced)
|
60.62M | 19.52% |
| keyboard_arrow_right |
These companies research, develop, and outsource the manufacturing of patented drugs.
|
||
| keyboard_arrow_down |
Royalties from Licensing of Pharma to Pharma Production Companies
Pre-Revenue Pharmaceuticals
|
11M | 3.54% |
| keyboard_arrow_right |
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
||